| HOME >> BIOLOGY >> TECHNOLOGY |
"We're very pleased to partner with eHealth Initiative and the other organizations in this effort," said Gretchen Dieck, Senior Vice President, Safety and Risk Management, Pfizer, Inc. "Our hope is that it will advance the quality of information we use to understand patients' experiences with our medicines. We owe it to patients, doctors and caregivers to deliver the most accurate, timely and useful information we have about the benefits and risks of our drugs."
Tim Garnett, MD, Vice President, Global Patient Safety, Eli Lilly and Company noted, "Early detection of safety signals is a vital part of our continued efforts to provide safe and effective medicines to patients. We are proud to partner with eHealth Initiative as part of our ongoing efforts to identify safety signals quickly and accurately and to communicate risk and benefit data. Innovations such as this, involving both academia and the pharmaceutical industry, take advantage of our complementary expertise and will be an important part of future efforts to ensure the safety of the medicines we develop."
As part of the project, eHI will adopt and apply commonly accepted principles and policies for assuring the privacy, confidentiality and security of health care information. eHI will also conduct research and develop legal guidance documents and model agreements to facilitate responsible handling of information for drug safety purposes by others in the field that are exploring use of health information for safety-related purposes. Educational strategies and materials will be developed to support effective communication of the importance of using electronic clinical information for safety, and the safeguards that are in place to assure patient privacy.
"Detecting adverse drug or device events is y
'/>"/>
| SOURCE eHealth Initiative Copyright©2007 PR Newswire. All rights reserved |